Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.
about
Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptomeAutophagy attenuates noise-induced hearing loss by reducing oxidative stressAblation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells.Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes.Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.Chronically increased S6K1 is associated with impaired IRS1 signaling in skeletal muscle of GDM women with impaired glucose tolerance postpartummTORC1 signaling and regulation of pancreatic β-cell mass.Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells.Identification of sucrose non-fermenting-related kinase (SNRK) as a suppressor of adipocyte inflammationBone Marrow Mesenchymal Stem Cells (BM-MSCs) Improve Heart Function in Swine Myocardial Infarction Model through Paracrine Effects.Insulin activates RSK (p90 ribosomal S6 kinase) to trigger a new negative feedback loop that regulates insulin signaling for glucose metabolism.Targeting the Mammalian Target of Rapamycin in Lung Cancer.mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling.Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions.Metabolic regulation of adipose tissue macrophage (ATM) function in obesity and diabetes.Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice.Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.p(⁷⁰S⁶K¹) in the TORC1 pathway is essential for the differentiation of Th17 Cells, but not Th1, Th2, or Treg cells in mice.Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.Blockade of the acute activation of mTOR complex 1 decreases hypertrophy development in rats with severe aortic valve regurgitation.Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes.Intracellular lipid metabolism impairs β cell compensation during diet-induced obesity.PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats.Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease.eIF4E-Dependent Translational Control: A Central Mechanism for Regulation of Pain Plasticity
P2860
Q28305597-7F6A5C41-AFD9-4977-9D26-C57E09DA072EQ30383378-BD3A8CB4-FFB1-4036-AA0F-119E6A980331Q33812880-5AAF17ED-D7C7-44E0-BD0D-A8A32D6E6C76Q33842810-D0B097EC-B5E6-46B3-BF3D-4D7E730DB599Q33849666-942EE5E7-A558-4D2F-BA7D-388E245DA655Q34077263-D2C559C8-48EF-4C24-B9D1-03B17D43298CQ34894537-1818B318-007F-45F2-A5F1-7CACCC201EAFQ35984067-D6B53AE4-FB6E-4FD6-979D-4AD8143B685AQ36760689-C431515E-E792-48F1-B43A-F37A096FBA96Q37014875-E9D42539-515C-4D63-9887-B070864C47E8Q37019466-3D662342-6F5D-40DA-91B2-7AAA351071D4Q37312198-BF35FA18-A4C6-4EC2-9599-42FFB39A11CFQ37741531-E3FC8948-9ACE-483E-8D80-1BAB1510739EQ37863123-7A16ADFE-4412-4F67-8735-D32F340DB4DEQ38017247-F8E1D36F-3245-427F-9BE8-EBF941F58D21Q38254279-5D18E064-E53B-46DC-8D9A-24FE084019E4Q38665200-149A997B-DFFE-4C73-9D62-F89C315C9FE3Q38806361-E8C93FCB-B2FA-455F-A1C2-303299FF8E45Q39182553-D276071A-5F24-47B8-9B9A-09E0FAFA7295Q40378528-6BF20999-CC1E-48C1-A6E8-84D8FE9CB51EQ40693029-2E8A00F6-8C35-4CCD-9357-F83D68D56751Q42042549-7A035265-88F4-472F-B1D2-248BE3AE19D1Q48215808-B7DA9A9D-FE8B-4F7F-9B99-8C7124F87A5BQ49851052-08EB53EA-56AC-4B56-8346-04F5A2800968Q51325820-980CF7F7-2A16-4CD3-ABBC-F4C700FC1EBFQ54117927-BEC12CCA-8C38-4930-B25B-249ED0ACB847Q59136306-A772DDE7-4F70-4B96-BF9A-F56CA949F6A9
P2860
Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@ast
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@en
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@nl
type
label
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@ast
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@en
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@nl
prefLabel
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@ast
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@en
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@nl
P2093
P2860
P356
P1476
Chronic inhibition of the mTOR ...... mulation in 3T3-L1 adipocytes.
@en
P2093
Alain Veilleux
André Marette
Kerstin Bellmann
Vanessa P Houde
P2860
P304
P356
10.1210/ME.2009-0328
P577
2010-03-04T00:00:00Z